Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a single arm open label trial to test the tolerability of the combination of monocyte
derived DCs loaded with KRN7000 (DC-KRN7000) and Lenalidomide (LEN) in patients with
asymptomatic myeloma. Phase I component of the study will evaluate the optimal dose of LEN,
with particular emphasis on safety. After an interim analysis of these data, a single dose
level will be chosen for phase II component in additional patients.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborators:
Celgene Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.